The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.
Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.
RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
A 20-year-old experiencing crown thinning is using a topical minoxidil/finasteride treatment and is concerned about shedding. Shedding is common and temporary, lasting weeks to months, and it's advised to continue the treatment as results can take up to a year.
Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.
A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.
The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.
The post discusses the user's experience with hair loss treatment using finasteride, clobetasol propionate, and ketoconazole shampoo. The conversation warns about the potential side effects of clobetasol, a powerful topical steroid, and emphasizes its short-term usage.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
A 20-year-old male shared progress pictures after three months of using 1mg oral finasteride daily, 5% minoxidil twice daily, and a 1.5mm dermaroller weekly. He reported significant hair regrowth.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
A 29-year-old shared their hair recovery progress using a liposomal topical finasteride/minoxidil solution, LLLT helmet, and vitamins, noting that transplants were only on the hairline. They highlighted the effectiveness of their regimen and addressed skepticism with photos.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A 20-year-old is experiencing a receding hairline and thinning at the crown, using minoxidil 5% for 15 days. It is suggested to continue minoxidil and consider adding finasteride and ketoconazole shampoo for better results.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
A user inquired about Cipla Tugain Men, a topical solution containing Minoxidil 5% and Finasteride 0.1%, noting its less greasy texture and good price. Responses suggest it's similar to other products with the same ingredients, questioning the effectiveness of additional components.
The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.
Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.
The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
A 20-year-old male shares his 2.5-month progress using 1mg finasteride, topical minoxidil, tretinoin, dermarolling, and ketoconazole for hair loss, noting slight libido decrease. Users discuss sourcing topical finasteride and request more photos to see the results.
A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.